Drug Trial Radar · NCT03470922
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
714
Actual
Start
Apr 11, 2018
Primary completion
Jan 25, 2021
Study completion Dec 15, 2030
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.
Conditions
- Melanoma
Interventions
RelatlimabBiological
Specified dose on specified day
NivolumabBiological
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From randomization to date of first documented tumor progression or death (up to approximately 33 months)
Locations
127 sites in 25 countries. Site status is shown where the registry gives one.
Local Institution - 0010
Tucson, Arizona
Local Institution - 0020
Los Angeles, California
Coastal Integrative Cancer Care
San Luis Obispo, California
Local Institution - 0116
Santa Barbara, California
Local Institution - 0012
Washington D.C., District of Columbia
Local Institution - 0013
Jacksonville, Florida
Local Institution - 0117
Orlando, Florida
Local Institution - 0007
Tampa, Florida
Local Institution - 0038
Atlanta, Georgia
Local Institution - 0016
Chicago, Illinois
Local Institution - 0114
Fort Wayne, Indiana
Local Institution - 0077
Baltimore, Maryland
Local Institution - 0120
Baltimore, Maryland
Local Institution - 0014
Boston, Massachusetts
Local Institution - 0134
Boston, Massachusetts
Local Institution - 0015
Ann Arbor, Michigan
Local Institution - 0009
Minneapolis, Minnesota
Local Institution - 0011
Rochester, Minnesota
Local Institution - 0018
Charlotte, North Carolina
Local Institution - 0019
Allentown, Pennsylvania
Local Institution - 0076
Dallas, Texas
Local Institution - 0008
Houston, Texas
Local Institution - 0004
Buenos Aires, Argentina
Local Institution - 0003
Buenos Aires, Argentina
Local Institution - 0005
Buenos Aires, Argentina
Local Institution - 0135
Buenos Aires, Distrito Federal, Argentina
Local Institution - 0002
Capital Federal, Distrito Federal, Argentina
Local Institution - 0042
North Sydney, New South Wales, Australia
Local Institution - 0043
Waratah, New South Wales, Australia
Local Institution - 0041
Greenslopes, Queensland, Australia
Local Institution - 0045
Southport, Queensland, Australia
Local Institution - 0133
Bedford Park, South Australia, Australia
Local Institution - 0044
Murdoch, Western Australia, Australia
Local Institution - 0037
Salzburg, Austria
Local Institution - 0035
Vienna, Austria
Local Institution - 0036
Graz, Styria, Austria
Local Institution - 0047
Brussels, Belgium
Local Institution - 0049
Brussels, Belgium
Local Institution - 0048
Ghent, Belgium
Local Institution - 0059
Rio de Janiro, Brazil
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.